Robert A. Colbert, MD, PhD | Issue: April 2010 |
New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…
The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…
HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.